No Data
No Data
No Data
No Data
No Data
Haoyuan Pharmaceutical (688131.SH)'s net profit for the first quarter of 167.574 million yuan decreased by 63.76% year-on-year
Gelonghui, April 29丨Haoyuan Pharmaceutical (688131.SH) released its report for the first quarter of 2024. Operating revenue during the reporting period was 505 million yuan, up 20.68% year on year; net profit attributable to shareholders of listed companies was 16.7574 million yuan, a year-on-year decrease of 63.76%; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 13.922,300 yuan, a year-on-year decrease of 66.82%, with basic earnings per share of 0.11 yuan.
Gelonghui FinanceApr 29 06:21 ET
Haoyuan Pharmaceutical (688131.SH) announced its 2023 annual results, with net profit of 127 million yuan, a year-on-year decrease of 34.18%
According to the Zhitong Finance App, Haoyuan Pharmaceutical (688131.SH) disclosed its 2023 annual report. The company achieved revenue of 1.88 billion yuan in 2023, an increase of 38.44%; net profit to mother was 127 million yuan, a year-on-year decrease of 34.18%; deducted non-net profit of 110 million yuan, a year-on-year decrease of 29.58%; and basic earnings per share were 0.85 yuan. The company plans to pay a cash dividend of 1.50 yuan (tax included) for every 10 shares, adding 4 shares for every 10 shares.
Zhitong FinanceApr 24 10:52 ET
Should Weakness in Shanghai Haoyuan Chemexpress Co., Ltd.'s (SHSE:688131) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
Shanghai Haoyuan Chemexpress (SHSE:688131) has had a rough three months with its share price down 33%. However, stock prices are usually driven by a company's financials over the long term, which in
Simply Wall StApr 16 20:09 ET
Haoyuan Chemexpress to Issue 822 Million Yuan Worth of Convertible Bonds
Shanghai Haoyuan Chemexpress (SHA:688131) proposed to issue convertible corporate bonds worth up to 822.4 million yuan, the company said in its filing on the Shanghai Stock Exchange. The proceeds from
MT NewswiresMar 25 04:08 ET
Haoyuan Chemexpress to Raise Subsidiary's Capital by 200 Million Yuan
Shanghai Haoyuan Chemexpress (SHA:688131) plans to raise the capital of subsidiary Anhui Haoyuan Pharmaceutical by 200 million yuan through debt-for-equity swaps, the company said in the filing on the
MT NewswiresMar 25 04:04 ET
Haoyuan Pharmaceutical (688131.SH): Capital increase of 200 million yuan for wholly-owned subsidiary through debt-to-equity swaps
Gelonghui, March 22丨Haoyuan Pharmaceutical (688131.SH) announced that on March 22, 2024, the company held the 34th meeting of the 3rd board of directors and the 32nd meeting of the 3rd board of supervisors to review and pass the “Proposal on Increasing the Capital of Wholly-owned Subsidiaries by using debt-for-equity swaps”, and agreed that the company would use funds raised to increase the capital of Anhui Haoyuan by RMB 20.00 million. After the capital increase was completed, the registered capital of Anhui Haoyuan increased from RMB 20 million to RMB 40 million. It is a wholly-owned subsidiary of the company.
Gelonghui FinanceMar 22 06:40 ET
No Data
No Data